Heterogeneity of Efficacy and Safety of Antiplatelet Therapy in Cardiovascular and Cerebrovascular Disease

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.10, Iss.2, 2010-04, pp. : 115-124

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?

Current Pharmaceutical Design, Vol. 19, Iss. 21, 2013-06 ,pp. : 3788-3794

Bentham Science Publishers

Access to resources Recommend Favorite

Antiplatelet Agents for the Prevention of Cardiovascular Disease in Diabetes Mellitus

By Colwell John A.

American Journal of Cardiovascular Drugs, Vol. 4, Iss. 2, 2004-01 ,pp. : 87-106

Adis International

Access to resources Recommend Favorite

A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases

Current Pharmaceutical Design, Vol. 21, Iss. 35, 2015-10 ,pp. : 5101-5107

Bentham Science Publishers

Access to resources Recommend Favorite

Antiplatelet Agents in the Prevention of Cardiovascular Morbidity and Mortality in Older Patients With Vascular Disease

By Aronow W.S.

Drugs & Aging, Vol. 15, Iss. 2, 1999-08 ,pp. : 91-101

Adis International

Access to resources Recommend Favorite

Editorial (Thematic Issue: Antiplatelet Treatment in Cardiovascular Disease: New Insights)

Current Pharmaceutical Design, Vol. 22, Iss. 29, 2016-09 ,pp. : 4491-4492

Bentham Science Publishers

Access to resources Recommend Favorite